Home > Back to Publisher > Report Information

The 2009-2014 World Outlook for Chiral-Based Products

Icon Group International, Inc.
January 8, 2009
191 Pages - SKU: ICN2098673

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

This econometric study covers the world outlook for chiral-based products across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the 230 countries of the world). This study gives, however, my estimates for the worldwide latent demand, or the P.I.E. for chiral-based products. It also shows how the P.I.E. is divided across the world’s regional and national markets. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business.

1 INTRODUCTION: 1.1 Overview; 1.2 What is Latent Demand and the P.I.E.?; 1.3 The Methodology
2 SUMMARY OF FINDINGS: 2.1 The Worldwide Market Potential
3 ASIA & OCEANA: 3.1 Executive Summary; 3.2 American Samoa; 3.3 Australia; 3.4 Bangladesh; 3.5 Bhutan; 3.6 Brunei; 3.7 Burma; 3.8 Cambodia; 3.9 China; 3.10 Christmas Island; 3.11 Cook Islands; 3.12 Fiji; 3.13 French Polynesia; 3.14 Guam; 3.15 Hong Kong; 3.16 India; 3.17 Indonesia; 3.18 Japan; 3.19 Kiribati; 3.20 Laos; 3.21 Macau; 3.22 Malaysia; 3.23 Maldives; 3.24 Marshall Islands; 3.25 Micronesia Federation; 3.26 Mongolia; 3.27 Nauru; 3.28 Nepal; 3.29 New Caledonia; 3.30 New Zealand; 3.31 Niue; 3.32 Norfolk Island; 3.33 North Korea; 3.34 Palau; 3.35 Papua New Guinea; 3.36 Philippines; 3.37 Seychelles; 3.38 Singapore; 3.39 Solomon Islands; 3.40 South Korea; 3.41 Sri Lanka; 3.42 Taiwan; 3.43 Thailand; 3.44 The Northern Mariana Island; 3.45 Tokelau; 3.46 Tonga; 3.47 Tuvalu; 3.48 Vanuatu; 3.49 Vietnam; 3.50 Wallis and Futuna; 3.51 Western Samoa
4 EUROPE: 4.1 Executive Summary; 4.2 Albania; 4.3 Andorra; 4.4 Austria; 4.5 Belarus; 4.6 Belgium; 4.7 Bosnia and Herzegovina; 4.8 Bulgaria; 4.9 Croatia; 4.10 Cyprus; 4.11 Czech Republic; 4.12 Denmark; 4.13 Estonia; 4.14 Finland; 4.15 France; 4.16 Georgia; 4.17 Germany; 4.18 Greece; 4.19 Hungary; 4.20 Iceland; 4.21 Ireland; 4.22 Italy; 4.23 Kazakhstan; 4.24 Latvia; 4.25 Liechtenstein; 4.26 Lithuania; 4.27 Luxembourg; 4.28 Malta; 4.29 Moldova; 4.30 Monaco; 4.31 Norway; 4.32 Poland; 4.33 Portugal; 4.34 Romania; 4.35 Russia; 4.36 San Marino; 4.37 Slovakia; 4.38 Slovenia; 4.39 Spain; 4.40 Sweden; 4.41 Switzerland; 4.42 The Netherlands; 4.43 The United Kingdom; 4.44 Ukraine
5 THE AMERICAS & THE CARIBBEAN: 5.1 Executive Summary; 5.2 Antigua and Barbuda; 5.3 Argentina; 5.4 Aruba; 5.5 Barbados; 5.6 Belize; 5.7 Bermuda; 5.8 Bolivia; 5.9 Brazil; 5.10 Canada; 5.11 Chile; 5.12 Colombia; 5.13 Costa Rica; 5.14 Cuba; 5.15 Dominica; 5.16 Dominican Republic; 5.17 Ecuador; 5.18 El Salvador; 5.19 French Guiana; 5.20 Greenland; 5.21 Grenada; 5.22 Guadeloupe; 5.23 Guatemala; 5.24 Guyana; 5.25 Haiti; 5.26 Honduras; 5.27 Jamaica; 5.28 Martinique; 5.29 Mexico; 5.30 Nicaragua; 5.31 Panama; 5.32 Paraguay; 5.33 Peru; 5.34 Puerto Rico; 5.35 St. Kitts and Nevis; 5.36 St. Lucia; 5.37 St. Vincent and the Grenadines; 5.38 Suriname; 5.39 The Bahamas; 5.40 The British Virgin Islands; 5.41 The Cayman Islands; 5.42 The Falkland Islands; 5.43 The Netherlands Antilles; 5.44 The U.S. Virgin Islands; 5.45 The United States; 5.46 Trinidad and Tobago; 5.47 Uruguay; 5.48 Venezuela
6 THE MIDDLE EAST & AFRICA: 6.1 Executive Summary; 6.2 Afghanistan; 6.3 Algeria; 6.4 Angola; 6.5 Armenia; 6.6 Azerbaijan; 6.7 Bahrain; 6.8 Benin; 6.9 Botswana; 6.10 Burkina Faso; 6.11 Burundi; 6.12 Cameroon; 6.13 Cape Verde; 6.14 Central African Republic; 6.15 Chad; 6.16 Comoros; 6.17 Congo (formerly Zaire); 6.18 Cote d'Ivoire; 6.19 Djibouti; 6.20 Egypt; 6.21 Equatorial Guinea; 6.22 Ethiopia; 6.23 Gabon; 6.24 Ghana; 6.25 Guinea; 6.26 Guinea-Bissau; 6.27 Iran; 6.28 Iraq; 6.29 Israel; 6.30 Jordan; 6.31 Kenya; 6.32 Kuwait; 6.33 Kyrgyzstan; 6.34 Lebanon; 6.35 Lesotho; 6.36 Liberia; 6.37 Libya; 6.38 Madagascar; 6.39 Malawi; 6.40 Mali; 6.41 Mauritania; 6.42 Mauritius; 6.43 Morocco; 6.44 Mozambique; 6.45 Namibia; 6.46 Niger; 6.47 Nigeria; 6.48 Oman; 6.49 Pakistan; 6.50 Palestine; 6.51 Qatar; 6.52 Republic of Congo; 6.53 Reunion; 6.54 Rwanda; 6.55 Sao Tome E Principe; 6.56 Saudi Arabia; 6.57 Senegal; 6.58 Sierra Leone; 6.59 Somalia; 6.60 South Africa; 6.61 Sudan; 6.62 Swaziland; 6.63 Syrian Arab Republic; 6.64 Tajikistan; 6.65 Tanzania; 6.66 The Gambia; 6.67 The United Arab Emirates; 6.68 Togo; 6.69 Tunisia; 6.70 Turkey; 6.71 Turkmenistan; 6.72 Uganda; 6.73 Uzbekistan; 6.74 Western Sahara; 6.75 Yemen; 6.76 Zambia; 6.77 Zimbabwe
7 DISCLAIMERS, WARRANTEES, AND USER AGREEMENT PROVISIONS: 7.1 Disclaimers & Safe Harbor; 7.2 Icon Group International, Inc. User Agreement Provisions

More Global Drug Discovery Reports

Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition by Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, ...

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2012 by GlobalData
Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2012 provides data on the Non-Alcoholic Steatohepatitis ...

Tachycardia (Tachyarrhythmias) Global Clinical Trials Review, H1, 2012 by GlobalData
Tachycardia (Tachyarrhythmias) Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Tachycardia (Tachyarrhythmias) Global Clinical Trials Review, H1, 2012 provides data on the Tachycardia (Tachyarrhythmias) ...

Restless Legs Syndrome Global Clinical Trials Review, H1, 2012 by GlobalData
Restless Legs Syndrome Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Restless Legs Syndrome Global Clinical Trials Review, H1, 2012 provides data on the ...

Lung Injury Global Clinical Trials Review, H1, 2012 by GlobalData
Lung Injury Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Lung Injury Global Clinical Trials Review, H1, 2012 provides data on the Lung Injury ...

See all reports like this >>

The 2009-2014 World Outlook for Chiral-Based Products

Share this report

Other tasks

Research Assistance

Related Markets

Drug Discovery Reports

Free Alert Me service